Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Synlogic (SYBX) up 7% after announcing SYNB1618 demonstrated clinically meaningful reductions of phenylalanine at several dose levels and SYNB1934 demonstrated two-fold higher activity than SYNB1618 in a head-to-head Phase 1 study in healthy volunteers
- Verastem (VSTM) up 19% after announcing a clinical collaboration agreement with Amgen (AMGN) to evaluate the combination of VS-6766, Verastem Oncology's investigational dual RAF/MEK inhibitor, with Amgen's KRAS G12C inhibitor Lumakras in KRAS G12C-mutant non-small cell lung cancer
- SmileDirectClub (SDC) up 5% as it is the highest trending ticker on WallStreetBets Reddit thread and is also in the top 10 on StockTwits in terms of message volume over the past 24 hours
- AstraZeneca (AZN) up 1% after announcing primary results from the Phase II DESTINY-Lung01 trial of Enhertu, the AstraZeneca and Daiichi Sankyo HER2-directed antibody drug conjugate, showed a robust and durable tumor response in previously treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer
- Cartesian Growth (GLBL) up 1% after Tiedemann Group, Alvarium Investments and the company jointly announceda definitive business combination agreement in which Alvarium Tiedemann's common stock is expected to be publicly traded on Nasdaq
DOWN AFTER EARNINGS -
- Cognyte (CGNT) down 7%
- Adagio Therapeutics (ADGI) down 4%
LOWER -
- Teladoc (TDOC) down 3% after COO David Sides resigned to become CEO of NexGen Healthcare (NXGN)
- Exelixis (EXEL) down 4% after announcing results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer